Home Healthcare Medical Devices Diabetes Devices Market

Diabetes Devices Market Size, Share & Trends Analysis Report By Type (Blood Glucose Monitoring Devices, Insulin Delivery Devices), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies, Others), By Application (Hospitals, Homecare, Diagnostics Centers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:

Diabetes Devices Market Size

The global diabetes devices market size was valued at USD 35.74 billion in 2025 and is projected to grow from USD 38.11 billion in 2026 to USD 63.64 billion by 2034, registering a CAGR of 6.62% during the forecast period from 2026 to 2034. North America dominated the diabetes devices market with a market share of 40.15% in 2025.

Factors like growing focus on diabetes care, technological innovations and product advancements drive market growth.

Diabetes mellitus, sometimes known as diabetes, is a series of metabolic conditions defined by a persistently high blood sugar level. Frequent urination, increased thirst, and increased appetite are common symptoms. Diabetes, if left untreated, can lead to a slew of health issues. Diabetic ketoacidosis, hyperosmolar hyperglycemia, and mortality are all examples of acute complications. Cardiovascular disease, stroke, chronic renal disease, foot ulcers, nerve damage, eye damage, and cognitive impairment are serious long-term consequences.

There are three primary forms of diabetes: Type 1 diabetes, Type 2 diabetes, and Gestational diabetes. Thus, the devices used to monitor diabetic conditions of patients are called diabetes devices or diabetes care devices.

Elements like a rise in the prevalence of obesity and technological advancements primarily drive the market. Additionally, rising diabetes prevalence and expanding use of insulin-delivery devices are propelling market expansion. Top manufacturers are concentrating on technological advancements and developing cutting-edge products to capture a sizeable portion of the market.

Diabetes Devices Market Size

Download a Free Sample To learn more about this report.

Type Insights

The market has been segmented into blood glucose monitoring devices and insulin delivery devices based on type. The insulin delivery devices segment is expected to dominate the market, and it is projected to reach USD 30,412.19 million by 2030, registering a CAGR of 7.62% during the forecast period.

Some of the primary driving reasons for the demand for insulin delivery devices are the rising number of regulations and approvals for technological advances in insulin delivery devices such as insulin pens, insulin pumps, jet injectors, and other devices. One of the factors driving the demand of insulin delivery devices is the increasing acceptance of insulin patches and smart insulin pumps for the self-management of diabetes.

Diabetes Devices Market Size By Segments

Request Customizationto receive a tailored report.

Distribution Channel Insights

The market has been segmented into hospitals, retail pharmacies, diabetes clinics/centers, online pharmacies, and others based on the distribution channel. The retail pharmacies segment is expected to dominate the market, and it is projected to reach USD 11,491.59 million by 2030, at a CAGR of 6.92% during the forecast. Rising penetration of private-label brands in retail outlets at discounted costs is one of the factors likely to drive the growth of the retail sales segment over the forecast period.

Due to high traffic and product availability, hospital pharmacies accounted for over 54.0% of market penetration in 2021. Inpatient and outpatient pharmacies are the two types of pharmacies that work on a hospital campus. The hospital has an inpatient pharmacy, but it is only accessible to authorized staff who work in the operating rooms, intensive care units, inpatient wards, and unique service areas. In contrast, outpatient pharmacies are typically found near hospital entrances and lobbies for patients. The outpatient pharmacy sells insulin delivery equipment and portable glucose meters.

Online pharmacies can offer customers lucrative discounts because they buy diabetes devices directly from manufacturers. The segment is driven primarily by rising public-private funding and increasing patient awareness of online pharmacies.

End-Use Insights

The market has been segmented into hospitals, home care, and diagnostic centers based on end-use. The hospital segment is expected to dominate the market, and it is projected to reach USD 19,845.68 million by 2030, at a CAGR of 6.42% during the forecast period. An increase in diabetic patients is driving hospital admission.

  • According to the American Diabetes Association, type 1 diabetes affects roughly 3 million children and adults in the United States. Compared to type 2 diabetes patients, type 1 diabetes patients experience more extended hospital stays and a greater mortality rate and complications. Patients with type 1 diabetes are given insulin to prevent ketoacidosis and have a greater rate of hyperglycemia.

Thus, an increase in the number of type 1 diabetes patients in hospitals and a rise in the demand for continuous blood glucose monitoring are two variables driving up hospital demand.

The homecare segment is expected to grow at a promising CAGR during the forecast period. The rise in public awareness of diabetes preventive care is credited with this expansion. The demand for insulin pumps in homecare settings is rising due to more government initiatives to raise diabetes awareness and the user-friendly interface of insulin pumps. Furthermore, the demand for home care is rising as the senior population grows.

Diabetes Devices Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Insights

With an expected market value of USD 18,943.58 million by 2030, at a CAGR of 6.28%, North America is expected to be the largest market for diabetes devices. Obesity's rising prevalence, expensive treatment costs, technology breakthroughs, and new product launches will drive the region forward.

  • The United States will likely dominate the North America market because of the high number of diabetics and the attractive reimbursement policies. The market is being driven by high per capita income and rising healthcare spending, among other things. Furthermore, the market is likely to be propelled by smart devices and technological breakthroughs such as the usage of AI and data analytics.

Europe: Fastest Growing Region with the Highest Cagr

With a market value of USD 15,281.94 million by 2030, at a CAGR of 6.35%, Europe is expected to be the second-largest market for diabetes devices. Over the forecast period, factors such as an increase in the number of diabetic patients and increased awareness about diabetes management and control are likely to contribute to the market growth.

In Asian nations like China and India, insulin delivery devices are widely used. The higher adoption of these devices in the APAC countries is due to rising diabetes awareness and a changing healthcare environment. Additionally, the increase in healthcare spending has prompted a rise in the use of technologically advanced products in nations like China and India, which is anticipated to accelerate market growth.

North America Diabetes Devices Market Revenue Share 2025

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Diabetes Devices Market

Medtronic
Abbott
Ascensia Diabetes Care Holdings AG
Dexcom Inc.
Hoffmann-La Roche Ltd.
Sanofi
Novo Nordisk A/S
Insulet Corporation
Ypsomed
Valeritas Inc

Key Industry Developments

July 9, 2026 – Novo Nordisk launched Awiqli® (insulin icodec), the world's first once-weekly basal insulin, in India for adults with type 1 and type 2 diabetes. The launch reduces insulin injections from 365 to 52 per year and marks India as the seventh global launch market for the therapy.
April 2026 – Dexcom received U.S. FDA clearance for the Dexcom G7 CGM with an extended 15-day sensor wear time for adults with diabetes. The enhanced device provides longer sensor life while maintaining real-time continuous glucose monitoring accuracy.
March 2026 – Tandem Diabetes Care commercially launched Control-IQ+, an advanced hybrid closed-loop insulin delivery algorithm compatible with the t:slim X2™ insulin pump and Tandem Mobi™ System. The technology expands automated insulin delivery support for people with type 1 diabetes (ages 2 years and older) and adults with type 2 diabetes.
January 2026 – Sanofi announced European Commission approval of Teizeild® (teplizumab) for delaying the onset of Stage 3 type 1 diabetes in eligible patients with Stage 2 disease. While a therapeutic product rather than a device, the approval supports broader adoption of advanced diabetes management technologies alongside early intervention strategies.

Report Scope

Segmentation

By Type 2
  • Blood Glucose Monitoring Devices
  • Insulin Delivery Devices
By Distribution Channel 5
  • Hospital Pharmacies
  • Retail Pharmacies
  • Diabetes Clinics/Centers
  • Online Pharmacies
  • Others
By Application 3
  • Hospitals
  • Homecare
  • Diagnostics Centers

Geographies Covered

North America 2
  • U.S.
  • Canada
Europe 8
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Russia
  • Nordic
  • Benelux
APAC 7
  • China
  • Korea
  • Japan
  • India
  • Australia
  • Taiwan
  • South East Asia
Middle East and Africa 6
  • UAE
  • Turkey
  • Saudi Arabia
  • South Africa
  • Egypt
  • Nigeria
LATAM 5
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
Competitive Coverage Medtronic · Abbott · Ascensia Diabetes Care Holdings AG · Dexcom Inc. · Hoffmann-La Roche Ltd.
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The diabetes devices market size is valued at USD 38.11 Billion in 2026 and is projected to reach USD 63.64 Billion by 2034, at a CAGR of 6.62% during the forecast period 2026-2034.

North America dominated the market with a share of 40.15% in 2025.

The leading players in this market are Medtronic, Abbott, Ascensia Diabetes Care Holdings AG, Dexcom Inc., Hoffmann-La Roche Ltd..

The diabetes devices market is projected to grow at a CAGR of 6.62% during the forecast period of 2026 2034.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: